Risk factors for relapse after discontinuation of tenofovir or entecavir in hepatitis B e antigen-negative patients.

In this model, there was no independent risk factor, but there was a significant trend between the probability of relapse and use of TDF as the last NA treatment before discontinuation (p=0.070) ( Table 2 ).

also in 9,775 other papers